Veltuzumab

Unknown Manufacturer

Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

Overview

Veltuzumab is a monoclonal antibody which, as of October 2009, is undergoing Phase I/II clinical trials for the treatment of non-Hodgkin's lymphoma.

Investigated for use/treatment in lymphoma (non-hodgkin's).

Technical identifiers

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US 8349332 B2Applicant: IBC PHARMACEUTICALS INCPriority: 2011
US
6 publications
Method for preparation of a high concentration liquid formulation of an antibody
EP 2727602 A1Applicant: TAKEDA GMBHPriority: 2012
CN
EP
US
3 publications
Structural variants of antibodies for improved therapeutic characteristics
- US 8287864 B2
  Applicant: GOLDENBERG DAVID MPriority: 2009
  US
  3 publications
- US 7919273 B2
  Applicant: IMMUNOMEDICS INCPriority: 2009
  US
  3 publications